--- title: "Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions" type: "News" locale: "en" url: "https://longbridge.com/en/news/290233235.md" description: "BofA Securities initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $27 price target, citing NXC-201's potential in AL amyloidosis. Analysts project peak sales near $963 million based on strong Phase 2 complete response rates. However, they flagged risks regarding long-term durability, safety concerns in frail patients, and commercial adoption challenges related to CAR-T logistics." datetime: "2026-06-18T17:38:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290233235.md) - [en](https://longbridge.com/en/news/290233235.md) - [zh-HK](https://longbridge.com/zh-HK/news/290233235.md) --- # Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions Bank of America (BofA) Securities initiated coverage on **Immix Biopharma Inc.** (NASDAQ:IMMX), driven by NXC-201 in AL amyloidosis. AL amyloidosis is a rare plasma cell disorder wherein abnormal plasma cells in the bone marrow overproduce misfolded antibody proteins (light chains). These proteins clump together as amyloid deposits, progressively damaging vital organs. **Read Also: Why Is Prothena Stock Trading Lower On Tuesday?** ## Strong Clinical Data Supports Bullish View In an investor note on Thursday, **Bank of America Securities** (BofA) assumed NXC-201 will launch in the U.S. in 2028 based on current timelines. It estimates a 50% likelihood-of-success based on developmental stage and models worldwide risk-adjusted peak sales of $963 million. **Analyst Tazeen** Ahmad wrote, “We view NXC-201 in r/r AL as a compelling opportunity given high CR rates and no approved therapies. BofA analyst initiated coverage of Immix Biopharma with a Buy rating and price forecast of $27. In May, the company reported a 95% complete response rate in its clinical trial for relapsed/refractory AL amyloidosis. The company said 19 of the first 20 patients treated with NXC-201 achieved a complete response within one year, with no relapses reported to date. It plans to begin a Phase 3 trial in newly diagnosed AL amyloidosis patients, with the next clinical update expected in September 2026. In January, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to NXC-201 for relapsed/refractory AL Amyloidosis. The designation was based on Phase 2 NXC-201 interim data from the NEXICART-2 trial. ## BofA Highlights Risks To Commercial Adoption BofA questions whether the early high CR rates will hold up with longer follow-up. Safety remains critical in this frail population, as even modest increases in cytokine release syndrome, neurotoxicity, or cardiac events could limit real-world adoption. Access may also constrain near-term uptake, with CAR-T manufacturing, logistics, and treatment center capacity potentially limiting use as demand for other CAR-T therapies grows. Risks to BofA Buy thesis include durability uncertainty, potential (and unexpected) safety issues in larger studies, emerging competition including BCMA CAR-Ts and bispecifics, and a slower-than-expected commercial ramp. “However, we think NXC-201’s strong efficacy and lack of treatment options support a favorable commercial setup for IMMX,” BofA wrote on Thursday. **IMMX Stock Price Activity**: Immix Biopharma shares were up 2.52% at $9.90 at the time of publication on Thursday, according to Benzinga Pro data. **Read Also: Joe Rogan Says Former Presidents Contacted Spotify Behind The Scenes To Push For His Show's Removal: 'They Spent A Lot Of Money'** _Photo: Faces Portrait/Shutterstock_ ### Related Stocks - [IMMX.US](https://longbridge.com/en/quote/IMMX.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [PRTA.US](https://longbridge.com/en/quote/PRTA.US.md) - [SPOT.US](https://longbridge.com/en/quote/SPOT.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Needham & Company LLC](https://longbridge.com/en/news/293471721.md) - [Immix Biopharma posts corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis](https://longbridge.com/en/news/291677993.md) - [EUDA Health signs MOU with GO POSB, SIIT to develop off-the-shelf iPSC cell therapies](https://longbridge.com/en/news/294340008.md) - [Kyverna signs commercial manufacturing, supply deal with ElevateBio for miv-cel CAR-T therapy](https://longbridge.com/en/news/293928704.md) - [Pacira transitions PCRX-201 gene therapy to scalable commercial manufacturing process in Phase 2 ASCEND study](https://longbridge.com/en/news/293929271.md)